Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Boulogne-Billancourt – page 143

3 430 clinical trials in Boulogne-Billancourt, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Boulogne-Billancourt at a glance
3 430
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 430 trials in Boulogne-Billancourt

Open in trial search

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Sjogren's syndrome

Not recruiting

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Chronic kidney disease+1

Not recruiting

A Study Testing How Well BAY 3401016 Works and How Safe It Is in Adults Aged 18 to 45 Years with Alport Syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:BAY 3401016
  • Sponsor:Bayer AG

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus+3

Not recruiting

A study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Uveal melanoma

Not recruiting

A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darovasertib
  • Sponsor:Ideaya Biosciences Inc.

Vitiligo

Not recruiting

A Study Testing Zasocitinib Compared to Placebo in Adults with Nonsegmental Vitiligo to See How Well It Works and How Safe It Is

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

A Study of Tarperprumig Safety and Effectiveness in Adults with Blood Vessel Inflammation Caused by ANCA Antibodies

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tarperprumig
  • Sponsor:Alexion Pharmaceuticals Inc.

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Boulogne-Billancourt

What the registry says about research in the country

01 Lung Cancer Research

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) and novel treatment approaches, including immunotherapy combinations and targeted therapies.

  • Advanced stage treatment evaluation
  • Immunotherapy effectiveness
  • Combination therapy assessment

Studies investigating various treatment strategies for both elderly patients and those with specific genetic mutations.

02 Melanoma Studies

Research centered on advanced melanoma treatment, particularly in high-risk stages and post-surgical care.

  • Adjuvant therapy trials
  • Stage III melanoma management
  • Immunotherapy protocols

Focus on improving survival rates through targeted therapeutic approaches and immune system modulation.

03 Kidney and Cardiovascular Research

Investigations into chronic kidney disease (CKD) treatment and cardiac conditions, including innovative therapeutic combinations.

  • Blood pressure management
  • Cardiac function improvement
  • Disease progression prevention

Studies evaluating new treatment approaches for patients with complex cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.